Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Javelin Pharmaceuticals

Request full access

Javelin Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the research, development, and commercialization of products

Cambridge, United StatesFounded 1998Biotech & Life Sciences

About Javelin Pharmaceuticals

Javelin Pharmaceuticals, Inc. was a specialty pharmaceutical company established in 1998 by Fred Mermelstein to address unmet needs in the pain management market. Initially known as Intrac, the Cambridge, Massachusetts-based firm focused on applying proprietary technologies to develop novel drugs and enhance existing ones. The company's primary market was hospital-based pain management, targeting conditions such as post-operative, cancer, post-trauma, and procedural pain.

The company's lead product candidate was Dyloject, an injectable formulation of diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID). This product was developed as a non-opioid alternative for managing moderate-to-severe post-operative pain, a significant area of need given the adverse side effects associated with traditional opioids. Dyloject received marketing approval in the United Kingdom and was submitted for approval to the U.S. Food and Drug Administration (FDA). Javelin's pipeline also included other pain treatments in advanced clinical development, such as Ereska (intranasal ketamine) and Rylomine (intranasal morphine).

After a series of funding rounds, including a PIPE deal in 2005 and going public, Javelin's trajectory culminated in an acquisition. In 2010, after a bidding process that also involved Myriad Pharmaceuticals, Javelin entered into a definitive merger agreement with Hospira, Inc., a global specialty pharmaceutical company. Hospira acquired Javelin for approximately $145 million, viewing Dyloject as a strategic fit with its own portfolio, particularly its sedation agent Precedex, as both were marketed to anesthesiologists. The acquisition was completed in mid-2010, and Javelin became a wholly-owned subsidiary of Hospira, which itself was later acquired by Pfizer.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
13
Open positions
None listed
Dealroom signal
23.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Dec 2009 $95M $95M Myriad Genetics —
GRANTOther financing Jul 2006 $750K — National Cancer Institute (NCI) —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Javelin Pharmaceuticals website traffic

Latest recorded traffic for Javelin Pharmaceuticals is 41K monthly website visits. Javelin Pharmaceuticals's team declined 18.8% over the past year.

Latest monthly visits41K 1-year team growth-18.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Javelin Pharmaceuticals in the Cambridge ecosystem

Live from Dealroom

The Javelin Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Cancer Institute (NCI)

Series B and later1 investor entered at this stage

  • Wexford Capital

Other known investors1 additional known investor

  • Myriad Genetics
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇮🇳 India100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Javelin Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Javelin Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.